EMA defends changes to data disclosure policy as 'a reasonable compromise'
This article was originally published in SRA
Executive Summary
There is 'absolutely no change in direction' in the European Medicines Agency's draft policy on the proactive publication of clinical trial data, and changes made to the way that data can be accessed represent a 'reasonable compromise', says its executive director Guido Rasi1.